This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, T.
Right arrow Articles by Drlica, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, T.
Right arrow Articles by Drlica, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2001, p. 2703-2709, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2703-2709.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Enhancement of Fluoroquinolone Activity by C-8 Halogen and Methoxy Moieties: Action against a Gyrase Resistance Mutant of Mycobacterium smegmatis and a Gyrase-Topoisomerase IV Double Mutant of Staphylococcus aureus

Tao Lu,1 Xilin Zhao,1 Xinying Li,1 Alex Drlica-Wagner,1 Jian-Ying Wang,1 John Domagala,2 and Karl Drlica1,*

Public Health Research Institute, New York, New York 10016,1 and Parke-Davis Research Division, Warner-Lambert Company, Ann Arbor, Michigan 481052

Received 4 December 2000/Returned for modification 10 January 2001/Accepted 6 July 2001

The increasing prevalence of antibiotic resistance among bacterial pathogens prompted a microbiological study of fluoroquinolone structure-activity relationships with resistant mutants. Bacteriostatic and bactericidal activities for 12 fluoroquinolones were examined with a gyrase mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. For both organisms C-8 halogen and C-8 methoxy groups enhanced activity. The MIC at which 99% of the isolates tested were inhibited (MIC99) was reduced three- to fivefold for the M. smegmatis mutant and seven- to eightfold for the S. aureus mutant by C-8 bromine, chlorine, and methoxy groups. With both organisms a smaller reduction in the MIC99 (two- to threefold) was associated with a C-8 fluorine moiety. In most comparisons with M. smegmatis the response to a C-8 substituent was similar (within twofold) for wild-type and mutant cells. In contrast, mutant S. aureus was affected more than the wild type by the addition of a C-8 substituent. C-8 halogen and methoxy groups also improved the ability to kill the two mutants and the respective wild-type cells when measured with various fluoroquinolone concentrations during an incubation period equivalent to four to five doubling times. Collectively these data help define a group of fluoroquinolones that can serve (i) as a base for structure refinement and (ii) as test compounds for slowing the development of fluoroquinolone resistance during infection of vertebrate hosts.

* Corresponding author. Mailing address: Public Health Research Institute, 455 First Ave., New York, NY 10016. Phone: (212) 578-0830. Fax: (212) 578-0804. E-mail:drlica{at}phri.nyu.edu.

Antimicrobial Agents and Chemotherapy, October 2001, p. 2703-2709, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2703-2709.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Becnel Boyd, L., Maynard, M. J., Morgan-Linnell, S. K., Horton, L. B., Sucgang, R., Hamill, R. J., Jimenez, J. R., Versalovic, J., Steffen, D., Zechiedrich, L. (2009). Relationships among Ciprofloxacin, Gatifloxacin, Levofloxacin, and Norfloxacin MICs for Fluoroquinolone-Resistant Escherichia coli Clinical Isolates. Antimicrob. Agents Chemother. 53: 229-234 [Abstract] [Full Text]  
  • German, N., Malik, M., Rosen, J. D., Drlica, K., Kerns, R. J. (2008). Use of Gyrase Resistance Mutants To Guide Selection of 8-Methoxy-Quinazoline-2,4-Diones. Antimicrob. Agents Chemother. 52: 3915-3921 [Abstract] [Full Text]  
  • Silley, P., Stephan, B., Greife, H. A., Pridmore, A. (2007). Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats. J Antimicrob Chemother 60: 999-1003 [Abstract] [Full Text]  
  • LaPlante, K. L., Rybak, M. J., Tsuji, B., Lodise, T. P., Kaatz, G. W. (2007). Fluoroquinolone Resistance in Streptococcus pneumoniae: Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin. Antimicrob. Agents Chemother. 51: 1315-1320 [Abstract] [Full Text]  
  • Zhao, X., Quinn, B., Kerns, R., Drlica, K. (2006). Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 58: 1283-1286 [Abstract] [Full Text]  
  • Wetzstein, H.-G. (2005). Comparative Mutant Prevention Concentrations of Pradofloxacin and Other Veterinary Fluoroquinolones Indicate Differing Potentials in Preventing Selection of Resistance. Antimicrob. Agents Chemother. 49: 4166-4173 [Abstract] [Full Text]  
  • Aubry, A., Pan, X.-S., Fisher, L. M., Jarlier, V., Cambau, E. (2004). Mycobacterium tuberculosis DNA Gyrase: Interaction with Quinolones and Correlation with Antimycobacterial Drug Activity. Antimicrob. Agents Chemother. 48: 1281-1288 [Abstract] [Full Text]  
  • Cheng, A. F. B., Yew, W. W., Chan, E. W. C., Chin, M. L., Hui, M. M. M., Chan, R. C. Y. (2004). Multiplex PCR Amplimer Conformation Analysis for Rapid Detection of gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates. Antimicrob. Agents Chemother. 48: 596-601 [Abstract] [Full Text]  
  • Allen, G. P., Kaatz, G. W., Rybak, M. J. (2003). Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 47: 2606-2614 [Abstract] [Full Text]  
  • Drlica, K. (2003). The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52: 11-17 [Abstract] [Full Text]  
  • Zhao, X., Eisner, W., Perl-Rosenthal, N., Kreiswirth, B., Drlica, K. (2003). Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1023-1027 [Abstract] [Full Text]  
  • Takei, M., Fukuda, H., Kishii, R., Kadowaki, Y., Atobe, Y., Hosaka, M. (2002). Contribution of the C-8-Methoxy Group of Gatifloxacin to Inhibition of Type II Topoisomerases of Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 3337-3338 [Full Text]  
  • Li, X., Zhao, X., Drlica, K. (2002). Selection of Streptococcus pneumoniae Mutants Having Reduced Susceptibility to Moxifloxacin and Levofloxacin. Antimicrob. Agents Chemother. 46: 522-524 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»